Growth Stories With IBD

Over the last decade, cell therapies have attracted a lot of investor attention to biotechs. These groundbreaking treatments use a patient's own cells to create personalized medicine that not only improves wellness outcomes for people, but it has the ability to transform the health care and pharmaceutical industries.

On this Growth Stories Spotlight, we talk to Vericel CEO Nick Colangelo to get his insights on the cell therapy market, his plans to expand MACI and burn care treatments and why he thinks Vericel has a unique position in the competitive landscape.

Tesla is looking for its next big win. And the company is focusing on self-driving cars as a key part of its long-term strategy. On this Growth Stories Spotlight, we take a look at Tesla's upcoming robotaxi event and why the company is centering its future around a technology it's had trouble executing — and how the investing community might react.

What market saw record sales growth last year and is considered a disappointment? That would be electric vehicles.

Back in 2021, automakers went all in on battery-powered cars, committing billions of dollars to EV production. But just a few years later, that future is looking a bit hazy as a host of factors have seemingly put the brakes on the EV transition. And consumers who aren't ready to go all in on battery power are turning more and more to hybrid models.

On this episode of Growth Stories, we take a look at the evolving electric vehicle market and what those changes signify for automakers—and investors—as they navigate the EV transition.

Since its market debut in 2017, Celsius has been 'bubbling' up explosive growth for investors. But the company's turbocharged performance has set a high bar — leaving investors and Wall Street to wonder if Celsius' fast pace of growth is sustainable. On this Growth Stories Spotlight, Celsius CEO John Fieldly talks about the energy drink market and the growth drivers pushing Celsius forward in the year ahead.

On this Growth Stories Spotlight, Informatica CEO Amit Walia gives us details on how the AI megatrend is boosting cloud computing growth and why being the Switzerland of data is helping the company stand out in the competitive data management landscape.

Since its blockbuster return to the public market in September 2023, chip designer Arm has dazzled investors with its strong price history. And while the company is known for its mobile phone technology, CEO Rene Haas has signaled that Arm’s automotive segment is a key area of focus as the era of smart cars has upped the demand — and price — for the high-performing chips powering our vehicles. 

On this Growth Stories Spotlight, Arm’s head of automotive Dipti Vachani takes us on a deep dive into the chip designer’s strategy and why the company is focused on the auto segment as a pillar of future success.

It's been a bumpy ride for Tesla stock over the last year as the EV automaker deals with increased competition and softening demand. As Elon Musk tries to navigate the company through choppy growth waves, will investors' patience with Tesla chart the same course? IBD news editor Ed Carson breaks down the bull and bear cases for Tesla stock.

Adobe was one of the hottest stocks in 2023 thanks to the artificial intelligence tidal wave. But that growth has slowed as the AI feeding frenzy begins to settle. Adobe saw a similar pullback last year before the introduction of Firefly propelled shares higher. And with new AI powered-tools taking center stage at this year’s Adobe Summit, investors will find out if Adobe stock will sing a similar tune — or fall out of rhythm with the market.

On this Growth Stories Spotlight, we speak to Anil Chakravarthy, who heads the digital experience business at Adobe, to get an inside look at the company’s AI strategy and the road ahead.

Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using CRISPR technology to treat sickle cell disease.

Government approval of these groundbreaking treatments could generate an unprecedented wave of medical innovation. But gene editing therapies aren't without risk, and questions remain about the safety and cost effectiveness of these experimental treatments.

On this episode of Growth Stories, we dive into the science of gene editing treatments and how the boom in gene therapy drug approvals could transform the healthcare industry.

Microsoft became a dominant tech powerhouse when Windows PCs and Internet Explorer emerged as critical tools of the web revolution. Now the software giant is trying to regain its leadership role with generative artificial intelligence — and Wall Street is paying close attention. On this episode of Growth Stories, we look at Microsoft’s push into artificial intelligence — and how the tech titan plans to use that technology to fuel a new era of growth.